Innovation
DPC is working to ensure that there are appropriate incentives in the Medicare ESRD program to encourage innovation in the field. We are also partnering with members of the kidney and greater medical community to provide the patient voice in new research projects. All those affected by kidney disease know how vital access to high quality care is to living a full and meaningful life. DPC is committed to working with the kidney community to ensure that all care provided in this country meets the highest quality and patient safety standards so all of our members can live life to the fullest.
Related Information
DPC Comment Letter to CMS Recounts Heartbreaking Story of Rural Dialysis Clinic Closure
DPC has submitted its comments responding to this year’s Medicare ESRD Payment Rule. The Medicare agency is proposing a payment update of only 1.9%, which doesn’t keep pace with increasing costs. According to the [...]
DPC’s Letter to Dr. Mehmet Oz, Administrator at Centers for Medicare & Medicaid Services, on ESRD Prospective Payment System
August 27, 2025 The Honorable Mehmet Oz Administrator Centers for Medicare & Medicaid Services 200 Independence Avenue, SW Washington, DC 20001 Re: CMS-1830-P - End-Stage Renal Disease Prospective Payment System Dear Dr. Oz: Dialysis [...]
DPC Comments to CMS Sound Alarm on Workforce Shortages
In our comments responding to Medicare’s annual ESRD Payment Rule, DPC took the government to task over payment updates that lag increases in labor costs and failure to effectively cover new drugs for dialysis [...]
DPC Asks Medicare Officials to Reverse Pruritis Drug Fiasco
In a letter to the Center for Medicare and Medicaid Services (CMS), Dialysis Patient Citizens (DPC) asked for a “do-over” in the rollout of Korsuva, a drug that treats ESRD-related pruritis. Medicare makes an add-on [...]
DPC’s Letter to Hon. Jonathan Blum, Principal Deputy Administrator for CMS, on New Drugs in the ESRD PPS
June 11, 2024 The Honorable Jonathan Blum Principal Deputy Administrator Centers for Medicare & Medicaid Services 200 Independence Avenue, SW Washington, DC 20515 Re: New drugs in the ESRD PPS Dear Principal Deputy Administrator [...]
DPC Seeks Information on Patients’ Experience With Itching
A couple of years ago, a new drug was approved to treat ESRD-related pruritis. Medicare approved an additional payment for the drug Korsuva for a period of 2 years. But, because of the short expiration [...]
